Cardlytics, Inc. (NASDAQ:CDLX – Get Free Report) CEO Amit Gupta sold 5,964 shares of the stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $3.67, for a total value of $21,887.88. Following the transaction, the chief executive officer now owns 186,904 shares in the company, valued at approximately $685,937.68. This trade represents a 3.09 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Amit Gupta also recently made the following trade(s):
- On Thursday, October 24th, Amit Gupta sold 22,607 shares of Cardlytics stock. The shares were sold at an average price of $3.85, for a total value of $87,036.95.
Cardlytics Stock Performance
NASDAQ CDLX opened at $3.44 on Wednesday. The firm’s 50 day simple moving average is $3.90 and its 200 day simple moving average is $4.78. The firm has a market capitalization of $174.83 million, a price-to-earnings ratio of -0.56 and a beta of 1.53. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 2.40. Cardlytics, Inc. has a 1 year low of $2.89 and a 1 year high of $20.52.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the business. Atom Investors LP acquired a new stake in shares of Cardlytics in the 3rd quarter valued at approximately $33,000. SG Americas Securities LLC acquired a new stake in Cardlytics in the third quarter valued at approximately $45,000. Intech Investment Management LLC bought a new stake in shares of Cardlytics during the third quarter worth $47,000. Quadrature Capital Ltd acquired a new position in shares of Cardlytics during the third quarter worth $63,000. Finally, BNP Paribas Financial Markets lifted its stake in shares of Cardlytics by 32.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 19,745 shares of the company’s stock valued at $63,000 after acquiring an additional 4,796 shares during the last quarter. Institutional investors and hedge funds own 68.10% of the company’s stock.
Analyst Upgrades and Downgrades
Several research firms recently commented on CDLX. Craig Hallum upgraded shares of Cardlytics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 6th. Evercore ISI started coverage on shares of Cardlytics in a research report on Friday, October 11th. They set an “in-line” rating and a $4.00 target price on the stock. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Cardlytics in a research report on Thursday, November 7th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Cardlytics has an average rating of “Hold” and a consensus price target of $6.92.
Read Our Latest Analysis on CDLX
About Cardlytics
Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.
Featured Stories
- Five stocks we like better than Cardlytics
- What is the Dow Jones Industrial Average (DJIA)?
- Disney: Forging a 3-Headed Sports Streaming Giant With Fubo Deal
- 5 Top Rated Dividend Stocks to Consider
- How Buffett’s Best and Worst Stock Bets Have Fared 5 Years Later
- How to Use Stock Screeners to Find Stocks
- Bill Ackman’s Bold Case for Fannie Mae and Freddie Mac
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.